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5 Introduction 
Albumin is the most abundant plasma protein in the human body. It has a 
number of important physiological functions and binds a number of drugs. 
Hypoalbuminemia is a marker of disease and a predictor of outcome. Albumin 
solutions have been available in clinical practice since the Second World War. 
Despite our widespread experience with and extensive research into albumin 
solutions, there is still widespread controversy regarding their place in modern 
clinical medicine. 
 
5.1 Intravenous fluids 
The intravenous administration of fluids is necessary in a number of situations to 
replace lost fluid or blood and to maintain the fluid balance in critically ill 
patients. It is common to divide the available intravenous fluids into two 
groups—crystalloids and colloids—based on their oncotic properties. 
Crystalloid solutions are aqueous solutions of low-molecular-weight ions (salts) 
with or without glucose, whereas colloids also contain high-molecular-weight 
substances, such as proteins or large glucose polymers (1). 
 
A wide range of crystalloid solutions is available, varying in their compositions 
and concentrations of salts. The most common crystalloids in clinical practice 
are normal saline (isotonic NaCl), Ringer’s lactate solution (isotonic 
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physiological solution), and 5% glucose (hypotonic). A number of hypertonic 
solutions are also available for electrolyte replacement and rapid volume 
resuscitation. 
 
Colloid solutions contain high-molecular-weight substances, derived from 
plasma proteins or synthetic glucose polymers, suspended in an electrolyte 
solution. The high-molecular-weight substances present in colloid solutions 
exert an osmotic activity that tends to maintain these solutions intravascularly. 
The only blood-derived colloids commonly available in Europe are albumin 
solutions with variable albumin contents, typically in the range of 5%–25%. 
Albumin solutions will be discussed in more detail later in this thesis. Synthetic 
colloids include gelatins and dextrose starches. Haemaccel® is a gelatinous 
solution derived from bovine material, but because of histamine-mediated 
allergic reactions and fear of disease transmission, gelatin-derived solutions have 
fallen from favor in many countries. Dextran and hetastarches are examples of 
dextrose-starch-derived colloids. Dextran is a complex glucan composed of 
chains of variable length. Dextran solutions are described on the basis of the 
molecular weight of the dextran present in the solution. Dextran 40 
(Rheomacrodex, MW 40,000 Da) and dextran 70 (Macrodex, MW 70,000 Da) 
are used in clinical practice. Dextran 70 is the better volume expander, but 
dextran 40 is utilized for its advantageous effects on the microcirculation. A 
number of different hydroxyethyl starch solutions are available, with different 
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molecular weights and degrees of molar substitution (the proportion of glucose 
units in the starch molecule that have been replaced with hydroxyethyl units). 
The effects and adverse effects of these solutions are dependent on their 
composition (2). Hydroxyethyl starches are the synthetic colloids most 
commonly used in clinical practice. 
 
There are extensive controversies in the medical community regarding the use of 
colloids and crystalloids, and the appropriate types of colloids and crystalloids 
that should be used are debated. However, there is agreement about several 
characteristics of these solutions, and several generalizations can be made (1). 
1. Crystalloids, when given in sufficient amounts, can be just as effective as 
colloids in restoring the intravascular volume. 
2. Replacing an intravascular volume deficit with crystalloids requires three 
to four times the volume required when using colloids. 
3. Most surgical patients have an extracellular fluid deficit that exceeds 
their intravascular deficit. 
4. A severe intravascular fluid deficit can be more rapidly corrected using 
colloid solutions. 
5. The rapid administration of large amounts of crystalloids is more 
frequently associated with tissue edema. 
Despite these differences, it has been difficult to prove the superiority of one 
type of fluid over the other in the clinical context. There have been many 
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attempts to produce convincing evidence in this field using meta-analyses of the 
available research. However, the heterogeneity and diversity of the available 
trials and the complex clinical situation have made it difficult to draw firm 
conclusions. 
 
5.2 Pharmacotherapy 
Pharmacotherapy is the use of drugs to prevent, treat, or cure a disease or 
alleviate its symptoms. Modern pharmacotherapy includes an array of different 
substances, ranging from natural products from plants and animals to synthetic 
chemical compounds. Biotechnology has also supplied us with therapeutic 
agents in the form of various proteins, antibodies, and enzymes. In recent years, 
gene therapy has emerged as a promising new prospect. The science or art of 
pharmacotherapy is undoubtedly very complex. The sheer number of different 
drugs, the variability of these drugs, and the intrapatient variability makes this a 
difficult science from which to generalize or to comprehend fully. The literature 
in this field of medicine is immense. 
 
To better describe pharmacotherapy, it is traditionally separated into two distinct 
parts: pharmacokinetics (PK), or what the body does to the drug, and 
pharmacodynamics (PD), or what the drug does to the body. 
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5.2.1 Pharmacokinetics 
The pharmacokinetic processes that drugs undergo are absorption, distribution, 
metabolism, and excretion. The absorption of a drug is influenced by several 
variables, such as the route of administration (oral, intravenous, intramuscular, 
subcutaneous, transdermal, inhalation, etc.), its solubility, and its lipophilicity. 
After the drug is absorbed, the fraction of the dose that escapes metabolism and 
the efflux transporters in the gut wall and enters the systemic circulation is 
distributed about the body. The degree and rate of distribution is dependent on 
the size, the solubility, and the protein binding of the drug molecules. The 
distribution of a drug in the body is described by the apparent volume of 
distribution. This is a variable that relates the total amount of drug in the body to 
the plasma concentration. Drug metabolism is the process whereby the body 
transforms the drug from its original form, often to a water-soluble form that can 
be excreted. Metabolism can occur in many organs, such as the liver, kidney, 
plasma, and intestine, with the liver the predominant site of metabolism. When 
drugs are metabolized, they can change into either an inactive drug that can be 
excreted or an active metabolite that has its own pharmacological effect. An 
example of the latter is morphine, which is converted into morphine-6-
glucuronide, a potent analgesic in its own right. Some drugs are administered in 
the form of a prodrug, and the metabolite is the active drug. Mycophenolate 
mofetil (MMF) is one such inactive prodrug and is only active when 
metabolized into mycophenolic acid (MPA). A drug can be excreted from the 
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body via the liver, kidney, saliva, respiratory tract, etc. The rate of excretion is 
described as the drug’s half-life, which is the time it takes for 50% of the drug to 
be eliminated. The pharmacokinetic properties of a drug are patient dependent 
and may vary with age, weight, sex, and ethnicity. These properties may also be 
altered by disease. 
 
5.2.2 Pharmacodynamics 
“Pharmacodynamics” describes the biological and physiological effects of a 
drug on the body. The term refers to the mechanisms of the drug action and the 
relationship between the drug’s concentration and its effect. For the drug to have 
an effect, it must bind to an effect site or receptor. When a drug binds to a 
receptor, it either elicits a response (agonist) or blocks the receptor (antagonist), 
preventing the normal physiological action at the receptor site. Desired effects 
are termed “responses” or “effects”, whereas undesired effects are termed “side 
effects” or “adverse effects”. The amount of drug required to achieve a 
particular therapeutic response varies among individuals, and this is described 
by a dose–response curve and expresses the potency of the drug. The therapeutic 
index describes the relationship between the desired effect and the toxic effect of 
a drug. The therapeutic window is the dosage range between the minimum 
effective dose and the minimum toxic dose. 
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The PK and PD of a drug are patient dependent and may change in an individual 
patient over time. Of particular interest are the changes that occur in the 
critically ill and during surgery. 
 
5.2.3 PK and PD in critically ill patients 
The pharmacological effects of some drugs (e.g., sedatives, vasopressors, and 
antihypertensive drugs) commonly used to treat critically ill patients can be 
monitored easily and the dose titrated according to their responses (3). However, 
the effects of many other drugs, such as antibiotics, immunosuppressants, 
anticonvulsants, anti-inflammatory drugs, and anticancer drugs cannot be 
immediately observed, and clinical dose titration is not possible. Knowledge of 
how the pathophysiology of critically ill patients changes the PK and PD of 
drugs is therefore essential to optimize drug doses to achieve the 
pharmacodynamic targets. 
 
In septic patients, endotoxins may stimulate the production of various 
endogenous mediators that can affect the vascular endothelium, resulting in 
either vasoconstriction or vasodilatation, with the maldistribution of the blood 
flow, endothelial damage, and increased capillary permeability (4). Increased 
systemic vascular permeability occurs within hours of inflammatory stimuli, 
such as surgery or sepsis (5). Capillary leakage results in fluid shifts from the 
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intravascular compartment to the interstitial space (6). The shift of fluids from 
the intravascular compartment increases the apparent volume of distribution for 
hydrophilic drugs, which reduces the plasma drug concentration. The apparent 
volume of distribution of hydrophilic drugs may also be increased by the 
presence of mechanical ventilation, hypoalbuminemia, extracorporeal circuits, 
and significant burn injuries (6). These changes in apparent volume of 
distribution are of little importance for lipophilic drugs. 
 
In critically ill patients, the cardiac output can be either increased as a result of 
vasodilatation, fluid resuscitation, or stimulation with vasoactive drugs, or 
reduced as a result of vasoconstriction, hypovolemia, or cardiac dysfunction. 
Changes in the cardiac output can alter the perfusion of the metabolizing organs, 
increasing or reducing the clearance of a drug. Enhanced renal elimination of 
circulating drugs has been described with increasing regularity in the critically 
ill (7). 
 
The various treatments instituted for critically ill patients have implications for 
PD. The polypharmacy applied in any such patient entails potential drug–drug 
interactions. Renal replacement therapy is becoming increasingly common in 
this patient group and can influence the PK of drugs. The effect of renal 
replacement therapy on PK is dependent on the drug in question and the 
modality of the renal replacement used. Extracorporeal membrane oxygenation 
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can influence the drug PK by increasing the volume of its distribution, and by 
the possible binding of the drugs to the circuit (8). 
 
The consequences of altered PK depend on the pharmacodynamic properties 
associated with the optimal activity of an individual drug. -Lactam antibiotics, 
for example, are time-dependent antibiotics, and the time at which the serum 
level exceeds the minimum inhibitory concentration is the major 
pharmacodynamic index associated with the drug’s efficacy, and as such, the 
goal of dosing is to optimize the duration of the systematic exposure to the drug 
(9). For such drugs, increased clearance should justify a more frequent dosing 
regimen or continuous infusion. On the contrary, concentration-dependent 
killing antibiotics, such as aminoglycosides, are dependent on the peak drug 
concentration for their maximal bactericidal effect (9). For drugs with such 
profiles, increased apparent volume of distribution would justify an increased 
dose. 
 
5.2.4 Pharmacotherapy and drug–protein binding 
Albumin and alpha-1 acid glycoprotein (AAG) are the most important drug-
binding proteins in the circulation (10;11). Whereas albumin is primarily 
responsible for the binding of acidic drugs, basic drugs display greater affinity 
for AAG (12). Albumin is the most abundant plasma protein, with a 
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physiological concentration in the range of 35–45 g/L. In contrast, AAG has a 
plasma concentration of only 0.4–1 g/L under normal conditions. The plasma 
concentration of albumin is frequently reduced in a variety of disease states, 
whereas AAG is an acute-phase protein and may therefore be elevated in a 
disease state. Both albumin and AAG are produced in the liver and liver disease 
may therefore markedly reduce the concentrations of these proteins. 
 
The degree to which they are bound by plasma proteins is one of the parameters 
that influence the PK of drugs. Changes in protein binding may alter the PK of a 
drug, thereby also altering its PD. 
 
The apparent volume of distribution of any drug is dependent on the binding 
properties of the drug in both the plasma and the tissues. The volume of 
distribution (Vd) may be expressed by the following formula: 
,
 
where VP represents the plasma volume, VT the tissue volume, fu the drug 
fraction unbound in the plasma, and fut the drug fraction unbound in the tissues. 
Therefore, the volume of distribution determines how readily a drug will be 
displaced from the blood into the tissue compartments. A high free fraction in 
the blood results in the movement of the drug from the blood/plasma to the 
tissue compartment, increasing the distribution of the drug. Conversely, a higher 
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free fraction in the tissue results in the movement of the drug from the tissue to 
the blood/plasma and a reduction in its volume of distribution (13). High levels 
of protein–drug binding in the blood/plasma confine the drug to the 
blood/plasma and restrict its movement to other compartments, resulting in a 
low apparent volume of distribution. 
 
The other PK parameter that is partly dependent on protein binding is the drug 
clearance. “Clearance” describes the degree to which an organ of elimination 
clears the blood of the drug and is dependent on the blood flow to the organ, 
protein binding, and enzymatic or secretory activity. The clearance (CL) of a 
drug by a specific organ is understood to be the product of the blood flow to the 
organ (Q) and the extraction capacity of the organ for the drug (E) (14). 
 CL = Q  E 
When the extraction capacity for a drug approaches 1, the blood arriving at the 
organ is completely cleared of the drug, and the clearance is then sensitive to 
changes in the blood flow but not to changes in the binding of the drug by 
plasma proteins or to enzymatic capacity. This pattern of clearance is termed 
“high-extraction clearance”. When the extraction ratio is lower than 1, the 
clearance is dependent on other factors, such as protein binding, enzymatic 
capacity, and membrane permeability, and this is known as “low-extraction 
clearance” or restrictive clearance. For drugs with a high extraction ratio, the 
eliminating organ is capable of removing all the drug presented to it, 
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independent of the binding of the drug to cells or plasma proteins. However, for 
drugs with a low extraction ratio, protein binding may be a limiting factor in the 
elimination of the drug. 
 
5.3 Albumin 
 
5.3.1 History 
The name “albumin” originates from the Latin word “albus” (white) or 
“albumen” (whiteness). The name was first used when early medical chemists 
proved the presence of proteins in various bodily fluids by heat coagulation and 
salt precipitation. The product resembled egg white and was therefore termed 
“albumen”. Hippocrates (c 460 BC–c 370 BC) first mentioned some of 
albumin’s physiological properties, but albumin was not properly identified, 
isolated, and named until the early 1800s. Before that time, the term “albumin” 
was used to describe protein precipitates from bodily fluids. Philippus von 
Hohenheim, known as Paracelsus (1493–1541) and one of the founders of 
medical chemistry, considered albumen in the urine (which he precipitated by 
the addition of acid) an important indicator of disease (15). 
 
The purification of proteins has since come a long way. In 1840, the first 
recorded dialysis was performed by the French physiologist, C. Denis. He placed 
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blood serum in a sac of intestine immersed in water and found that some of the 
protein precipitated as the salt was removed through the sac. Unlike the action of 
heat, this precipitation was reversible when a small amount of salt was added. 
The protein that was soluble in water without salt was called “albumin” and the 
protein that precipitated in little globules was called “globulin”. By the 
nineteenth century, chemists had refined crystallization, and albumin was one of 
the earliest proteins to be crystallized. In the 1930s, T. Svedberg and K. O. 
Petersen in Uppsala studied the proteins in blood serum with the new technique 
of ultracentrifugation (16). Further advances were made in the Svedberg 
laboratory when A. Tiselius applied the Schlieren optics developed by Svedberg 
to the technique of electrophoresis, and albumin was readily identified as the 
prominent anionic constituent (17). Electrophoresis has since continued to be the 
usual method for identifying and judging the purity of albumin solutions. 
 
5.3.2 Physiology 
Albumin is the most abundant protein in blood plasma, with a normal 
concentration in the range of 35–45 g/L. Structurally, it is a single peptide chain, 
consisting of 585 amino acids held in three homologous domains by 17 disulfide 
bonds, forming a heart-shaped molecule (18;19). It belongs to a multigene 
family of proteins that includes -fetoprotein and vitamin D-binding protein. 
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Albumin molecule 
 
Albumin is produced in the liver (20). Between 6% and 10% of the albumin pool 
is degraded per day, giving it a relatively long biological half-life of about 20 
days. Only ~40% of the total body albumin is located in the vascular 
compartment. The remainder is located in the tissues. The transfer rate of 
albumin from the plasma to the interstitial compartment is low in skeletal and 
cardiac tissues, and relatively high in visceral organs (21). 
 
Albumin is a molecule, with a variety of physiological functions. It is a major 
contributor to the colloid osmotic pressure and facilitates the transport, 
distribution, and metabolism of many endogenous substances, such as fatty 
acids, amino acids, bile, and hormones, and exogenous substances such as drugs. 
For many hormones and vitamins, albumin acts not only as a carrier, but also as 
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a reservoir. A number of endogenous and exogenous toxins are sequestered by 
albumin and, in that way, rendered harmless in the circulation. 
 
Serum albumin accounts for approximately 80% of the colloid osmotic pressure 
of plasma. This is caused by the molecular effect and by the extra osmotic 
pressure induced by the Donnan effect, whereby sodium, potassium, and other 
cations are held in the plasma by the negative charges surrounding the molecules 
(22). 
 
Many drugs bind reversibly to albumin. The binding of drugs to plasma proteins 
affects their distribution and rate of metabolism in the body by controlling their 
free active concentrations and providing reservoirs for them. The drug-binding 
properties of albumin have been extensively studied. Early binding studies 
revealed two primary and nonoverlapping drug-binding sites on albumin, with a 
third binding site quite selective for digitoxin only (23;24). Later 
crystallographic studies revealed that drug sites 1 and 2 are located on 
subdomains IIA and IIIA, respectively. The binding sites exhibit variable 
degrees of specificity, and displacement reactions have been described among 
drugs with the same binding site. The affinity for one drug at a specific binding 
site may also be altered as a consequence of the binding of a second drug at a 
different binding site because of a structural change along a common interface 
(18), or by the binding of fatty acids. More recent crystallographic work has 
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identified several other drug pockets on the protein, in addition to the two 
primary drug-binding sites in subdomains IIA and IIIA. These sites can also be 
specific binding sites for one or more drugs, acting as secondary binding sites 
for compounds with another primary binding site (25). 
 
Fatty acids have low solubility in aqueous solutions and therefore require a 
transporter in both the plasma and the interstitial compartment. Albumin is the 
primary transporter for fatty acids and plays a major role in fatty acid transfer 
between the capillary plasma and the cells utilizing them. The mechanism is 
unclear, but the interplay between plasma and interstitial albumin is probably 
critical (26). Seven binding sites for fatty acids have been identified on the 
albumin molecule (27;28). The binding of fatty acids to albumin induces 
conformational changes in drug site 1, increasing its affinity for some drugs 
(29). Although this effect appears to be relatively small, it demonstrates the 
complexity of the binding characteristics of albumin. Drug site 2 directly 
overlaps one of the high-affinity fatty-acid-binding sites. However, at 
physiological levels of fatty acids, this competition is not likely to be a problem 
because the residual concentrations of the drug-binding sites under these 
conditions are likely to be sufficient for drug binding (25). 
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5.3.3 Albumin solutions 
Human albumin solutions were developed in the United States during the 
Second World War to provide an alternative to blood and dried plasma for fluid 
resuscitation in military casualties (30). The first documented clinical use of 
albumin occurred on the December 8, 1941, when seven burn victims from the 
Pearl Harbor attack were treated with albumin solutions. 
 
Albumin for therapeutic use is predominantly derived from pooled human 
plasma, although both time-expired blood and, in some countries, placental 
material have been used as sources in the past (31). The traditional method for 
its isolation has been cold ethanol fractionation, first described by Cohn and 
colleagues in 1946 (32). In later years, some manufacturers have changed to the 
chromatographic processing of plasma, a process that provides both a purer 
product and a higher yield (31). Albumin solution has been pasteurized since the 
1940s (33), a process that has been proven very effective in preventing the 
transmission of disease (34). To prevent the denaturation of the albumin 
molecule during heating to 60 °C, stabilizers are added to the solution. Although 
the main methods used in the manufacturing process have remained unchanged 
for the past 60 years, the albumin solution has undergone continuous 
improvement to reduce the amount of impurities, damaged proteins, and 
unwanted substances in the end product (31). Different manufacturers use 
different production methods, which might affect the end product. It has been 
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demonstrated that albumin from different manufacturers has different levels of 
metal ions, which could generate damaging oxygen intermediates (35), and that 
certain batches of albumin solutions influence the expression of endothelial cell 
adhesion molecules (36). The manufacturing process may also oxidize the 
albumin molecule to different extents, affecting the properties of the end product 
(37). 
 
Although albumin solution has been used widely since the Second World War, it 
has been difficult to demonstrate that it has advantages over alternative fluids. 
Increasing controversy concerning its use was aroused after the Cochrane 
Injuries Group Albumin Reviewers reported possible excessive mortality after 
the administration of albumin to critically ill patients (38). Escalating prices and 
increasing concern regarding the administration of human products have further 
discredited albumin solutions. However, a large, multicenter, randomized, 
controlled trial reestablished the safety of albumin solutions in 2004 (39). 
Although albumin is considered safe and has been widely used for nearly seven 
decades, there are no clinical situations in which albumin solutions are 
indispensable. Despite the many important physiological properties of albumin 
and the fact that hypoalbuminemia is a predictor of increased morbidity and 
mortality, correcting hypoalbuminemia has not been proven beneficial; nor has 
albumin administration to hypovolemic patients been shown to be more 
favorable than the administration of crystalloids (39;40). 
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5.4 Mycophenolic acid (MPA) 
MPA was first isolated by Gosio in 1896 (41). Through the years, it has been 
investigated as an antibiotic, antiviral, antifungal, antitumor, and anti-
inflammatory agent. However, it is within the field of immunosuppression that 
MPA has gained a foothold as a therapeutic agent. It was first approved in 1995, 
with the brand name “CellCept”, as a rejection prophylaxis after renal allograft 
transplantation. 
 
5.4.1 Mechanism of MPA action 
MPA is a potent, selective, and noncompetitive reversible inhibitor of inosine 5-
monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in the de 
novo synthesis of guanine nucleotides (42). De novo purine synthesis is 
critically important for the proliferative responses of human T and B 
lymphocytes, and a reduction in guanine nucleotides leads to cell-cycle arrest 
because DNA synthesis is blocked (43). MPA is relatively selective because 
most other cell lines can utilize a salvage pathway to produce guanine. MPA is 
also fivefold more potent in its inhibition of the IMPDH type II isoform, which 
is expressed in activated T and B lymphocytes, than in its inhibition of the type I 
isoform, which is expressed in most other cell types (44). 
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5.4.2 Pharmacokinetics of MPA 
Mycophenolate mofetil (MMF), the 2-morpholinoethyl ester of MPA, is a 
prodrug of MPA. The prodrug demonstrates better bioavailability, less between-
patient variability, and a shorter time to its maximum concentration (45). After 
its oral administration, MMF is rapidly absorbed and metabolized to MPA, with 
a peak in the plasma MPA concentration after approximately 1 h. The 
bioavailability of MPA from orally administered MMF is estimated to be 94.1% 
relative to the intravenous route in healthy volunteers (46). However, according 
to the label of the commercially available product, the absolute bioavailability of 
MPA is 72% after the oral administration of MMF to renal transplant recipients. 
MPA undergoes enterohepatic recirculation, which is supported by the presence 
of mycophenolic acid 7-O-glucuronide  (MPAG) in the bile, and is evident as a 
secondary peak in plasma MPA after 6–12 h (47). 
 
More than 99% of MPA is retained in the plasma compartment (48;49) and the 
concentration does not decrease in response to hemodialysis, indicating its tight 
binding to plasma proteins (50). Approximately 98% of MPA is bound to 
albumin (51). The degree of albumin binding is dependent on the albumin 
concentration and renal function. Renal impairment reduces the binding of MPA 
to albumin because of both the direct effect of uremia and the accumulation of 
the metabolite MPAG, which displaces MPA from albumin (51;52). 
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The liver is the main metabolizing site for MPA, but the gut wall and kidney are 
also thought to contribute. The uridine diphosphate–glucuronosyltransferase 
(UGT) enzyme family is responsible for the metabolism of MPA to its 
metabolites MPAG and mycophenolic acid acyl glucuronide (AcMPAG) (53). 
MPAG is the primary metabolite and appears in the plasma at concentrations 
20–100-fold higher than that of MPA (54), and 60%–80% of MPAG is bound to 
albumin (48). AcMPAG is an active metabolite that inhibits IMPDH in vitro 
(55). MPA is a restrictively cleared drug, which means that its clearance is 
dependent on the free fraction of the drug (56). The administration of 
radiolabeled MPA has shown that 93% of the drug is eliminated in the urine, 
whereas 6% is eliminated in the feces (47). 
 
Drug interactions may influence the pharmacokinetics of MPA. MPA is 
commonly administered together with either cyclosporine A (CsA) or tacrolimus 
(TRL). Pharmacokinetic studies have demonstrated that significantly higher 
MPA concentrations were attained in patients when MMF was coadministered 
with TRL than when it was administered with CsA (57). It has been established 
in a rodent model that this difference occurs because CsA interferes with the 
enterohepatic recirculation of MPA (58). Steroids are another common 
constituent of immunosuppressive protocols, and these have been demonstrated 
to influence the pharmacokinetics of MPA (59). Steroids have also been shown 
to enhance the activity of the enzyme responsible for the metabolism of MPA 
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(60), thereby reducing its bioavailability. The bioavailability of MPA may also 
be reduced when it is coadministered with some antibiotics and antacids (61;62). 
The binding of MPA to plasma proteins is reduced by sodium salicylate and 
furosemide, which thus increase the free fraction of MPA (48). 
 
The many intrinsic and extrinsic factors that influence the absorption, 
enterohepatic recirculation, albumin binding, and metabolism of MPA give rise 
to considerable overall variability in its PK, both between individuals and within 
the same individual over time. Its unpredictable PK and the narrow therapeutic 
index of MPA, combined with the serious consequences of therapeutic failure 
and its potential dangerous adverse effects, constitute a powerful rationale for 
implementing therapeutic drug monitoring (TDM) for MPA. 
 
5.4.3 Therapeutic drug monitoring of MPA 
MMF was approved for clinical use in adult renal transplant recipients at a fixed 
dose of 2 g per day, and the efficacy of fixed-dose regimens has been established 
(63). However, because of the variability in the PK of MPA outlined above, the 
prediction of MPA exposure based solely on the dose can lead to MPA 
concentrations that are lower or higher than desired in individual patients, and 
both high inter- and intrapatient variability over time has been established 
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(64;65). Therefore, there has been increased interest and research into the TDM 
of MPA to optimize its efficacy and safety. 
 
Significant correlations have been established between the area under the curve 
(AUC) for the concentration –versus time curve for MPA and clinical outcomes 
(acute rejection and adverse events) in renal transplant patients (66-69). A 
relatively small, single-center clinical trial demonstrated that therapeutic MPA 
monitoring using a limited sampling strategy can reduce the risk of treatment 
failure and acute rejection in renal allograft recipients 12 months after 
transplantation, with no increase in adverse events (70). However, two large 
multicenter, randomized controlled trials comparing fixed-dose with 
concentration-controlled administration of MPA was less convincing, and both 
dosing strategies revealed a reluctance among clinicians to adhere to the target 
MPA levels (71;72). Considerable overlap has also been reported between the 
MPA AUC values of patients experiencing rejection and the values of those not 
experiencing rejection (73). This indicates that there is large variability in the 
pharmacodynamic response to MPA and suggests that a pharmacodynamic 
marker could be beneficial in optimizing MPA treatments. The 
pharmacodynamic response to MPA is also variable, depending on the 
expression of the IMPDH enzyme and possibly also on the induction of other 
enzymes by MPA treatment (74), and functional gene variants (75). A study that 
measured IMPDH activity in renal transplant recipients demonstrated that high 
 32 
pretransplant IMPDH activity was associated with organ transplant rejection 
(76), and Raggi et al. have reported that IMPDH activity is a reliable predictor of 
rejection episodes in renal transplant patients (77). Moreover, IMPDH activity 
can be reliably quantified and offers a way to describe the immunosuppression 
exerted by MPA. 
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6 Aims of the thesis 
Understanding the drug-binding properties of pharmaceutical-grade albumin and 
the consequences of changes in plasma albumin concentrations are the aims of 
this thesis. 
 
The specific objectives of the projects were as follows. 
 
1. To investigate the changes in the albumin-binding capacity and the free 
fraction of naproxen, warfarin, and digitoxin in patients transfused with 
pharmaceutical-grade albumin, compared with patients receiving a 
modified starch solution (Study 1). 
2. To investigate the displacement properties of the stabilizers present in 
pharmaceutical-grade albumin for naproxen in healthy volunteers (Study 
2). 
3. To explore the changes in plasma albumin in the early period following 
liver transplantation and to determine how the albumin concentration 
influences the free fraction of MPA; and to assess whether changes in the 
free fraction of MPA influence its PD (Study 3). 
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7 Methods 
 
7.1 Paper 1 
This study was a randomized study of 40 surgical patients undergoing major 
surgery. The patients were randomized to receive either albumin or a starch 
solution when there was a clinical indication for volume replacement. The 
randomization was computer based and handled by the hospital’s office for 
clinical research. We performed a block randomization with two blocks of 20 
patients. Interim analyses were performed after completion of the first block. No 
attempt was made to blind either the clinician or the laboratory staff. 
 
The serum samples were collected (i) when anesthesia was induced, (ii) after the 
total amount of albumin or starch had been administered during the surgical 
procedure, (iii) 5 h after sample 2, and (iv) on the first postoperative day. 
Digitoxin, warfarin, and naproxen were added to the serum samples to measure 
drug binding. The albumin and AAG concentrations were measured 
immunophelometrically. Tryptophan, N-acetyl-DL-tryptophan, digitoxin, 
warfarin, and naproxen were determined by high-performance liquid 
chromatography (HPLC). The free concentrations of the drugs were measured 
with ultrafiltration. 
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The percentage of free drug was calculated as the ratio of the ultrafiltrate (free) 
concentration to the total concentration. The number of specific binding sites 
and the dissociation constants were calculated according to Scatchard. The 
Mann–Whitney–Wilcoxon test was used to compare the two groups. The 
Wilcoxon signed-rank test was used for statistical analyses within groups. 
 
7.2 Paper 2 
This study was a randomized crossover study of six healthy volunteers. The 
study individuals were given three 250 mg naproxen tablets, at 08:00 h (T0), and 
were then randomized to receive 100 mL of albumin (200 mg/mL) or 100 mL of 
Ringer’s acetate solution over a period of 15 min, at T0+2.5 h. 
 
Serum samples were collected at T0+2 h and every 15 min for 1 h and 45 min, 
and thereafter every 30 min for the next 3 h. The albumin concentrations were 
measured immunonephelometrically. The N-acetyl-DL-tryptophan, caprylic acid, 
and naproxen concentrations were determined by HPLC. The free concentrations 
of naproxen were measured with ultrafiltration. 
 
The percentage of free drug was calculated as the ratio of the ultrafiltrate (free) 
to the total concentration. The half-life of N-acetyl-DL-tryptophan was calculated 
from the elimination rate constant found by determining the slope of the log-
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linear part of the elimination curve. Paired-sample t test were used to compare 
the two groups at the different sampling points. 
 
7.3 Paper 3 
This study was a prospective observational study of 20 liver transplant recipients 
treated with MMF. The transplant recipients were enrolled consecutively, 
depending on the laboratory and its sampling capacity. 
 
A series of blood samples was collected on two occasions from each patient. The 
first session was in the early posttransplantation period (3rd–4th days 
posttransplantation), and the second session was when the graft was established, 
approximately 2 wk after the first session. Each set of samples consisted of 10 
different measuring points. The first sample was taken before the intake of the 
morning dose of MMF at 9:00 h (T0), and further samples were collected at 
T0+30 min, T0+45 min, and T0+60 min. Subsequent samples were taken every 
30 min for the next 3 h. Total and free MPA (after ultrafiltration) were 
determined by HPLC. The IMPDH activity in the CD4+ cells was determined by 
incubating the lysates of the isolated cells with saturating amounts of substrate 
for 120 min. The xanthine produced was determined quantitatively with liquid 
chromatography coupled to electrospray ionization and tandem mass 
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spectrometry. The activity of IMPDH was expressed as the xanthine production 
rate during the incubation (pmol/106 cells/min). 
 
The percentage of free MPA was calculated as the ratio of the ultrafiltrate (free) 
to the total concentration. The drug exposure and enzymatic activity were 
expressed as the area under the concentration curve (AUC) and calculated with 
the trapezoidal method. We used Pearson’s product-moment correlation 
coefficient (r) to test the relationship between albumin and the free fraction of 
MPA (linear). Spearman’s rank order correlation (rho) was used to correlate 
MPA, free MPA, and free-fraction MPA with IMPDH activity (nonlinear). The 
related-samples Wilcoxon signed-rank test was used to compare session 1 and 
session 2. 
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8 Results 
 
8.1 Paper 1 
The groups were evenly balanced with regard to age, height, weight, and sex. 
The Starch group had a small but statistically significantly lower preoperative 
albumin concentration compared with that of the Albumin group. During 
surgery, the albumin concentration decreased by 38% in the Starch group, 
whereas the albumin concentration in the Albumin group remained unchanged 
throughout the experiment. The stabilizers in the pharmaceutical-grade albumin, 
N-acetyl-DL-tryptophan and caprylate, were detected in the sera after the 
infusion of albumin, decreasing rapidly in subsequent samples. In the Starch 
group, the percentages of free naproxen, warfarin, and digitoxin increased 
throughout the observation period. For naproxen and digitoxin, the increased 
free fraction was combined with an increased number of binding sites. Naproxen 
also exhibited an increase in its dissociation constant. In the Albumin group, the 
percentage of free naproxen and the dissociation constant for naproxen increased 
between sample 1 and sample 2. There was a marginal reduction in the amount 
of free warfarin in samples 2 and 3, followed by a reduction in the dissociation 
constant and number of binding sites in sample 3 only. The binding 
characteristics of digitoxin remained unchanged in this group. 
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In this experiment, we observed an increase in the percentages of free naproxen, 
warfarin, and digitoxin. This can be explained by the significant decline in the 
albumin concentration caused by bleeding, combined with the infusion of 
colloids and crystalloids. In the Albumin group, we only observed an increase in 
the percentage of naproxen. This increase coincided with the measured 
concentrations of the stabilizers. Thus, the presence of stabilizers in 
pharmaceutical albumin might explain the displacement of naproxen from its 
binding site, as hypothesized. However, we did not observe any changes in the 
binding parameters for digitoxin or any increased binding of warfarin. The lack 
of displacement reactions observed was probably caused by the relatively low 
and short-lasting concentrations of stabilizers detected in the sera. Furthermore, 
warfarin has a different binding site on albumin than digitoxin and naproxen. 
The binding of warfarin to albumin is further complicated by free fatty acids, 
which may both enhance the binding of warfarin to albumin or displace warfarin 
from albumin. 
 
This study demonstrates that the infusion of starch solutions results in a 
reduction in albumin concentration and a significant reduction in the binding 
parameters of albumin for naproxen, digitoxin, and warfarin. However, the 
infusion of albumin causes the albumin concentration to be maintained, with 
sustained binding properties, except for the binding of naproxen in a transient 
period when the stabilizers were at their peak concentrations. Because the 
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displacing properties of the stabilizers are short-lived, albumin infusions can 
have a positive impact on the PK of highly protein-bound drugs in patients with 
grave hypoalbuminemia. 
 
8.2 Paper 2 
This study had a crossover design. Therefore, the two groups were identical with 
regard to their baseline characteristics. During the infusion of albumin, the 
albumin concentration increased in all six individuals. In contrast, the infusion 
of Ringer’s acetate solution caused a marginal reduction in the mean albumin 
concentration. The mean free fraction of naproxen increased by 30% when 
albumin was infused, returning to baseline during the next 15–30 min. The 
naproxen values in the Ringer’s acetate group followed the expected course 
throughout our measurements. N-Acetyl-DL-tryptophan and caprylate appeared 
in our samples after the albumin was infused in the Albumin group. N-Acetyl-
DL-tryptophan had a half-life of approximately 30 min, whereas the caprylate 
half-life was less than 15 min. We detected no N-acetyl-DL-tryptophan or change 
in the caprylate values in the Ringer’s acetate group. 
 
This study has shown that the stabilizers present in pharmaceutical-grade 
albumin displace naproxen from its binding site on albumin. However, the effect 
is short-term and probably of little importance for most patients. Nonetheless, in 
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some patients treated simultaneously with potentially toxic albumin-bound drugs 
and albumin infusions, the levels of the pharmacologically active unbound drug 
might transiently reach unintended high concentrations. 
 
8.3 Paper 3 
The study included 12 male and eight female liver transplant recipients, 16 of 
who completed both sampling sessions. The MPA Cmax occurred at a median of 
1 h after dosing, and the minimum IMPDH activity occurred simultaneously. 
There was no statistically significant difference between session 1 and session 2 
with respect to the pharmacological variables, with the exception of free-
fraction MPA at Cmax, which was significantly higher in session 1 than in 
session 2. The free-fraction MPA AUC0–4h correlated negatively with the 
albumin value. The IMPDH area under the effect curve 0-4h (AUEC0–4h) 
correlated with the total and free MPA AUC0–4h for session 1, whereas there 
was no significant correlation for session 2. 
 
There was no statistically significant correlation between IMPDH AUEC0–4h and 
the free-fraction MPA AUC0–4h or the trough measurements of MPA, free MPA, 
or free-fraction MPA. The T0 measurement for IMPDH correlated with IMPDH 
AUEC0–4h for both sessions. The percentage inhibition of IMPDH correlated 
with the total MPA AUC0–4h for session 1 and session 2, whereas free MPA only 
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correlated significantly for session 1. The percentage inhibition of AUC also 
correlated with the T0 measurement of IMPDH for session 1 and the MPA Cmax 
for both sessions. The IMPDH at MPA Cmax correlated inversely with both MPA 
AUC0–4h and free MPA AUC0–4h for session 1 and with Cmax for total and free 
MPA and the T0 measurement of IMPDH for both sessions. 
 
Despite the large variation in free-fraction MPA, which correlated with the 
albumin level, our study indicates that total MPA is an equivalent or better 
predictor of the immunosuppressive response exerted by MPA than IMPDH 
activity in liver transplant recipients. However, the measurement of IMPDH 
activity is a promising approach to TDM in patients treated with MPA. The 
IMPDH T0 activity sample shows particular potential and should be 
investigated further. 
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9 Discussion 
The three studies included in this thesis deal with questions regarding albumin 
solutions and protein binding of drugs. The reason for embarking on this topic 
was the renewed attention directed toward pharmaceutical albumin solutions 
after the Cochrane Injuries Group Albumin Reviewers reported that the 
administration of albumin to critically ill patients was, in fact, dangerous and 
probably increased the mortality of these patients (38). Although the usefulness 
of albumin solutions has been debated on a regular basis, it has been difficult for 
many to accept that albumin solutions are in fact harmful. A number of letters 
were written to the BMJ in response to the original article, criticizing the way 
the meta-analysis was conducted and the conclusions drawn (78-83). Several 
explanations were postulated to explain the detrimental effects of albumin 
solutions (85). At our institution, we took an interest in the drug-binding 
properties of pharmaceutical-grade albumin. 
 
This interest in the drug-binding capacity of pharmaceutical-grade albumin was 
evoked by the discovery that an albumin assay (the Vitros “dry chemistry” 
bromocresol green albumin method) underestimated the albumin concentration 
in pharmaceutical-grade albumin compared with a manual method. These 
findings were reproduced in sera taken from patients who had received 
pharmaceutical-grade albumin (84). This suggested that the in vivo binding 
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properties and possibly the transport functions of pharmaceutical-grade albumin 
were less than those of endogenous albumin. One suggested explanation for the 
reduced binding capacity of pharmaceutical-grade albumin was the presence of 
stabilizers in the end product. The effect of the stabilizers in pharmaceutical-
grade albumin was further investigated by Olsen at al., who demonstrated that 
caprylic acid and N-acetyl-DL-tryptophan, used as stabilizers in the purification 
process when pharmaceutical albumin is manufactured, both markedly reduced 
the binding capacity of pharmaceutical-grade albumin in vitro (86). These 
findings possibly explain why pharmaceutical-grade albumin was not beneficial 
when administered to critically ill patients. If pharmaceutical-grade albumin 
does not exhibit the binding properties of endogenous albumin, albumin 
solutions are merely highly priced colloids. 
 
9.1 Drug–protein binding 
The binding of drugs by proteins is a tremendously complex science. The degree 
of protein binding of a particular drug depends on a number of variables: the 
affinity of the drug for the various protein-binding sites, the plasma 
concentration of the protein, the molar concentration of the drug relative to the 
molar concentration of the unoccupied plasma-binding sites, and the presence of 
endogenous or exogenous compounds that may compete with the drug for the 
binding sites on the protein (87). Furthermore, the effects of altered protein 
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binding are dependent on the route of administration, the hepatic extraction 
ratio, and the therapeutic index. 
 
The idea that protein-binding interactions can lead to clinically significant drug 
interactions emerged in the mid-1960s, with the discovery of markedly increased 
prothrombin times in patients treated with warfarin and phenylbutazone (88), 
and severe hypoglycemia in patients treated with sulfonamides and tolbutamide 
(89). The drugs involved in these interactions are highly protein bound. It was 
also demonstrated that phenylbutazone displaces warfarin from human serum 
albumin (90). Realistic theoretical arguments, supported by in vitro evidence and 
in vivo observations, led to the conclusion that these clinical interactions are 
caused by the displacement and increased free fraction of the drug. However, 
pharmacokinetic theory and the confirmation of other mechanisms to explain the 
observed interactions have since demonstrated that plasma-binding displacement 
rarely has any clinical significance. Nevertheless, the original description of a 
clinically significant protein-binding interaction was established and has since 
been difficult to eradicate. In most cases, displacement reactions and altered 
protein binding do not lead to any clinically significant interactions, and this has 
been the subject of a number of articles (87;91-93). However, they might have 
clinical relevance for some drugs in certain situations, and in TDM settings, they 
can be of major importance. I will discuss below when displacement interactions 
might be important, and the implications for TDM. 
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9.1.1 Displacement reactions 
The “free drug hypothesis” maintains that only the free drug is available to cross 
physiological membranes and to interact with receptors. Based on this notion, it 
is expected that the effect of a given drug will correlate more closely to 
measurements of the free drug concentration than to the total drug concentration. 
A change in the free drug concentration as a result of its altered protein binding 
is therefore assumed to alter the effect of a given drug. However, the situation is 
much more complex. A change in the free drug concentration has a number of 
consequences and the net result for its PD and PK can be difficult to predict. 
Furthermore, it is not necessarily the drug concentration in the serum (central 
compartment) that is of interest, but the drug concentration at the site of action, 
which is in turn dependent on the physicochemical properties of the drug (12). 
 
If drug A is displaced from its protein-binding site by drug B, the free fraction of 
drug A will increase acutely. The increased free fraction of drug A is then free to 
act at its receptor site and intuitively, one would expect the effect of drug A to 
increase. However, the increased concentration of the free drug is not only free 
to act at its receptor site, but is also available to be redistributed, metabolized, 
and excreted. So how can we predict the net effect of a displacement reaction? 
 
For any displacement reaction to be clinically relevant, the drug in question must 
have a relatively narrow therapeutic index, or the range between the 
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concentration of the drug that achieves the desired response and the 
concentration that results in toxicity. For drugs with a broad therapeutic index, a 
moderate change in their free concentration may not lead to any increase in their 
effect or toxicity. 
 
The redistribution of a displaced drug to a new equilibrium occurs rapidly and 
will have a buffering effect on the consequences of a displacement reaction. The 
amount of redistribution is, in turn, dependent on the volume of distribution of 
the particular drug. For a drug with a large volume of distribution (> 20 L), a 
displacement reaction would probably have minimal consequences for the free 
fraction of the drug because of its redistribution. However, for a drug with a 
relatively small volume of distribution (< 10 L), its redistribution will be modest 
because most of the drug is located in the central compartment (87). 
 
The consequence of a displacement reaction on the clearance of a drug is 
dependent on the ability of the clearing organ to remove the drug. If this 
capacity to clear the drug is limited (“restrictively cleared drug”), only a small 
fraction of the drug is eliminated on its passage through the clearing organ. For 
such drugs, the clearance is proportional to the free fraction of the drug, so an 
increase in the free fraction would lead to a proportional increase in the 
clearance of the unbound drug and the concentration of the unbound drug would 
return to the predisplaced value after a transient increase. For a drug that is 
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nonrestrictively cleared, the eliminating organ removes most of the drug 
presented to it. Clearance is then dependent on the blood flow to the eliminating 
organ, and is therefore not altered by an increase in the free fraction. 
Consequently, an increase in the free fraction of a drug caused by a displacement 
reaction can be sustained and potentially result in an increased effect (87). 
 
For drugs that have their site of action in the central compartment, the free 
unbound drug in the plasma is responsible for the interaction with the drug 
receptor and the clinical response. This is in contrast to drugs that must cross 
membranes to reach their target receptors, when the physiochemical properties 
of the drug and the involvement of drug transporters become factors (12). One 
example of this is the differential effects of morphine and oxycodone, both of 
which mediate their analgesic effects by binding to the -opioid receptor. In 
vitro, morphine has a 26-fold greater affinity for the receptor than oxycodone. 
From this, one would assume that morphine would be a much more potent 
analgesic than oxycodone. However, in vivo, the two analgesics are equipotent 
(94). The explanation for this finding is that the active transport of oxycodone 
results in a brain concentration of free oxycodone three times higher than that in 
the blood, whereas the free morphine concentration is merely 0.56 times higher 
than that in the blood (95). 
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For a displacement reaction to be clinically significant, the drug displaced must 
fulfill a number of criteria. Foremost, it must have a narrow therapeutic index. It 
must also be highly protein bound (> 80%), exhibit a relatively small volume of 
distribution, and be restrictively cleared.  
9.1.1.1 Pharmaceutical-grade albumin and displacement reactions 
The binding sites of the stabilizers in pharmaceutical albumin, N-acetyl-DL-
tryptophan and caprylic acid (C8 fatty acid) and their drug displacement 
properties have been described previously (86;96). The stabilizers have also 
been demonstrated to displace bilirubin from its binding site on albumin (97). 
The demonstrated poor binding properties of pharmaceutical-grade albumin in 
vitro, caused by the stabilizers in the solution, raises a number of questions. 
Does the displacing effect endure in vivo? Can the stabilizers alter the binding 
properties of endogenous albumin? Does this have any clinical significance? 
 
Our first study was designed to address these questions. We compared surgical 
patients transfused with albumin with those transfused with starch colloids. We 
were able to detect the stabilizers in the sera of the patients who received 
albumin, but the concentrations detected were relatively low and decreased 
rapidly in the subsequent samples. We conducted binding studies with three test 
drugs—naproxen, digitoxin, and warfarin—but only naproxen displayed reduced 
binding as a consequence of displacement. However, our results for the binding 
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studies were obscured by the unpredictable surgical setting, with variable 
transfusion requirements and transfusion rates, large fluid shifts, and 
hemodilution. To separate the effects of the stabilizers and to study the 
phenomena in closer detail, we proceeded to a study of healthy volunteers. In 
that study, we demonstrated the displacing effect on naproxen of 
pharmaceutical-grade albumin in vivo, but we also established the short half-
lives of the stabilizers in vivo and the rapid return to the baseline binding 
properties of albumin. N-acetyl-DL-tryptophan had a half-life of approximately 
30 min and caprylate a half-life of less than 15 min. However, the stabilizers 
only exerted significant displacing effects at their peak concentrations and had 
already disappeared in the redistribution phase. The very short-lived 
displacement effect of the stabilizers in pharmaceutical-grade albumin means 
that clinically significant drug interactions are unlikely in most clinical settings. 
Only during infusion and in a very short period thereafter will this effect be 
detectable. However, critically ill patients treated with highly protein-bound 
drugs with narrow therapeutic indices, while simultaneously receiving large 
volumes of pharmaceutical-grade albumin over a prolonged period, might be 
exposed to enhanced effects of these drugs. Of course, this is a relatively rare 
occurrence, but relatively large volumes of albumin are transfused into the 
pediatric intensive-care population, burn patients, patients undergoing ascites 
drainage, and patients in renal dialysis. If these patients are treated 
simultaneously with highly albumin-bound drugs with narrow therapeutic 
 51 
indices, interactions with potentially serious consequences could ensue. Drugs 
that possibly exhibit such properties include anticancer drugs, such as etoposide, 
and immunosuppressant drugs, such as MPA. However, unpublished in vitro 
data from our own research group suggest that MPA is not displaced from 
albumin by albumin stabilizers. In addition to these drugs, there are several 
drugs used as sedatives in the intensive-care setting, such as diazepam, fentanyl, 
and propofol, that might be potentiated by albumin infusions, although this is 
probably rarely clinically important. 
 
9.1.2 Pharmaceutical-grade albumin drug-binding properties 
The study we undertook with a surgical population demonstrated that patients 
transfused with an albumin solution had a higher drug-binding capacity than 
patients treated with a starch solution. This result is not very surprising, 
considering that the median albumin concentration was reduced by 38% in the 
Starch group and remained unchanged in the Albumin group. However, this 
indicates that the drug-binding capacity of pharmaceutical albumin is maintained 
in vivo after transfusion. Whether the conserved binding properties of albumin 
are something that can be utilized in clinical practice is not yet clear. 
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9.1.3 Possible therapeutic benefits of pharmaceutical-grade albumin 
Albumin plays important roles in various different physiological processes and 
equilibria, which distinguishes it from most other plasma proteins, which have 
specific functions in the body. Despite more than 70 years of experience using 
albumin solutions, there is still no clinical situation in which albumin has been 
proven to be superior to other fluids. The reason for this may well be that 
albumin solutions are not exceptionally beneficial or that the appropriate 
research has not been done. Much of the research has so far focused on the role 
of albumin as a volume replacement fluid. There has been little emphasis on the 
physiological functions of the albumin molecule or the opportunity to utilize it 
in targeted patient populations. Albumin fluids have also changed considerably 
over time, and the fluids are not uniform in their constituents, but can vary 
considerably from one manufacturer to another. Of course, this makes 
comparing different studies from different geographic areas and time periods 
difficult. Moreover, any potentially beneficial effects for individual patients 
might be lost in the study material when the research lacks focus. 
 
For research into albumin solutions to be advanced, it is important that albumin 
solutions are viewed as complex and possibly multifunctional products. The 
standardization of albumin solutions should not be limited to their protein 
content, but should include other properties, such as their binding capacities and 
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antioxidant and anti-inflammatory potentials. The potential of albumin is being 
evaluated in several areas of medicine. 
 
The utilization of a number of properties of albumin has been attempted in the 
field of neuroprotection. In the context of experimental ischemic stroke, 
pharmaceutical albumin has been found to be neuroprotective by reducing brain 
swelling, preventing postischemic thrombosis, supplying an antioxidant activity, 
in hemodilution, and increasing the perfusion to the ischemic tissue (98). A 
large, ongoing, multicenter placebo-controlled trial is currently investigating the 
efficacy of albumin solutions in this patient group (99). Albumin has also been 
implicated in Alzheimer’s disease because of its amyloid-beta-binding capacity. 
A clinical trial including 29 patients showed the potential benefit of using a 
plasma exchange schedule with 5% albumin solution in the treatment of 
Alzheimer’s patients (100). Albumin infusions favorably influence the total 
plasma oxidant capacity in acute lung injury, and a randomized controlled trial 
of furosemide with and without albumin demonstrated favorable oxygenation in 
the Albumin group (101;102). In medical therapeutics, variable albumin levels 
can pose a challenge with regard to highly albumin-bound drugs with narrow 
therapeutic indices, as outlined in the text above. For patients undergoing 
chemotherapy with highly cytotoxic drugs, the use of albumin infusions to 
maintain stable albumin levels may be beneficial in improving the predictability 
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and safety of these drugs, because variable albumin levels can influence the PK 
of the drugs and thereby their effects and adverse effects. 
 
9.2 Protein binding and TDM 
When TDM of the plasma or blood concentration of a drug is performed on 
highly protein-bound drugs with narrow therapeutic indices to adjust the dose, it 
is important to know whether changes in protein binding might occur. Most 
routine TDM techniques measure the total drug concentration rather than the 
unbound concentration. This is not a problem for drugs that display 
concentration independent binding to plasma proteins; total drug measurements 
will predict the free drug concentration and the clinical effect. However, drugs 
that saturate the binding capacity of the protein display concentration-dependent 
protein binding, and total drug measurements might not accurately predict the 
clinical effect of the drug. 
 
There are several examples in the literature of how measurements of total drug 
concentrations might be misleading. Cortisol replacement therapy has been 
advocated based on the response to the cosyntropin stimulation test, which 
measures the total cortisol level. In a study that included critically ill patients 
with hypoalbuminemia, nearly 40% had subnormal total serum cortisol 
concentrations, despite a normal or elevated serum concentration of free cortisol 
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(103). Anticonvulsants, such as phenytoin, carbamazepine, and valproic acid, are 
strongly protein bound, mainly by albumin. The clinical utility of monitoring 
free phenytoin, free carbamazepine, and free valproic acid is well documented in 
the literature (104). Immunosuppressant drugs are another group of drugs that 
commonly combine a high degree of protein binding and narrow therapeutic 
indices, and MPA has been much debated in this regard. 
 
9.2.1 TDM of MPA 
The validity and usefulness of any TDM protocol require that the actual effect of 
the drug in question is measured. Whether the effect of the drug is best predicted 
by the total drug concentration, the free drug concentration, or some other 
measure depends on the properties of the specific drug and the clinical situation. 
A number of studies have demonstrated a correlation between MPA plasma 
concentrations and acute rejection episodes in a variety of transplant 
populations. In the renal transplant population, adjustment of the MPA dose 
based on the total drug concentration has been shown to be beneficial but 
difficult to accomplish (71;72). So far, TDM has not proven beneficial for liver 
transplant patients. Inter- and intrapatient variability over time may be more 
complex in the liver transplant population due to variable liver and kidney 
function and changing albumin concentrations. MPA is 98%–99% protein bound 
(54). An in vitro study demonstrated that increasing concentrations of MPA 
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were necessary to achieve 50% inhibition of IMPDH isoform II as the 
concentration of albumin was increased (48). Therefore, any change in protein 
binding or in the albumin concentration could have a major impact on the 
concentration of free MPA and consequently on IMPDH suppression. A recent 
study that included adult liver transplant recipients during the early 
posttransplantation period demonstrated high variability in the free MPA 
concentration and a lack of any relationship between the total and free 
concentrations of MPA. This suggests that the total MPA AUC should not be 
used to adapt the MMF dosing regimen during the early posttransplantation 
period (105). 
 
Variations in protein binding are not the only apparent limitation of MPA AUC 
measurements. There appears to be a considerable overlap in the MAP 
concentrations that result in rejection and those that do not (73), and different 
MPA doses seem to be required by African-Americans and Koreans compared 
with other ethnic groups, despite identical PD profiles (106). Therefore, it would 
seem advantageous to establish a pharmacodynamic measurement closer to the 
clinical outcome that would better reflect the net result of the pharmacokinetic 
and pharmacodynamic variability. 
 
In Study 3 in this thesis, we demonstrated a large variation in the free fraction of 
MPA and a negative correlation between albumin and the free fraction of MPA. 
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This significant variation in the free MPA concentration may have, but does not 
necessarily imply, clinical significance. To determine whether the variation in 
the free MPA concentration is clinically significant, it should be correlated with 
a marker of immunosuppression or a “hard” endpoint, such as organ rejection. 
 
IMPDH is the target enzyme for MPA, and IMPDH activity can be reliably 
quantified, so this offers a method of describing the immunosuppression exerted 
by MPA (107). Exactly how the measure of IMPDH activity is linked to the 
immunosuppressive response has not yet been fully established. The IMPDH 
AUEC value (Figure 1) is the most intuitive parameter, because this could be an 
absolute pharmacodynamic biomarker reflecting the variations in both IMPDH 
activity and MPA PK. However, we know that there is great interindividual 
variability in IMPDH activity (108). Whether this variable, IMPDH activity, 
should be reduced to an absolute value or reduced to a percentage of the T0 
(predose), pretransplantation, or washout value (measured in a sample from 
which all MPA is removed in vitro) is at present unclear. Furthermore, we do 
not know whether the IMPDH activity throughout the dosing interval or its 
maximum suppression is the best indication of the true immunosuppressive 
effect exerted by MPA. 
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Fig. 1. Example of MPA concentration and IMPDH activity in Liver transplantation patient 
treated with MPA (from study 3) 
 
In Study 3, we choose IMPDH activity in CD4+ cells as our marker of the MPA-
specific response. If the measured increase in the free fraction of MPA is to be 
clinically relevant, it must affect the IMPDH activity. The free fraction or 
concentration of MPA should therefore correlate better with the IMPDH activity 
than would the total MPA concentration. However, despite the large variation in 
the free fraction of MPA, the total and free MPA concentrations were equally 
good predictors of the immunosuppressive effect, as expressed by the IMPDH 
activity in CD4+ cells. Whether total or free MPA is the better predictor of the 
immunosuppressive effect exerted by MPA is debatable. An explanation for this 
finding might be that the measurement of the free drug is less robust than the 
measurement of the total drug because of the very low concentrations of free 
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drug measured. Therefore, the true significance of the free drug could be lost in 
the analytical process. This may be reflected in our study, in which 18% of the 
free MPA measurements were below the lowest limit of quantification. 
However, the assumption that only the free fraction of a drug is 
pharmacologically active may be overly simplistic. This theory is based on the 
hypothesis that only the free drug can act on the target receptors and that 
protein-bound drugs are inactive. This might be true to a certain extent, but the 
relationship between the kinetics of the extracellular protein binding and 
intracellular enzyme binding of a drug may, on the cellular level, produce an 
equilibrium that differs from the free versus total concentrations that we can 
measure in the plasma. 
 
We performed a number of correlation analyses in this study. The most robust 
and consistent correlation was found between T0 IMPDH (predose activity) and 
AUEC0–4h IMPDH. For this to be a clinically significant finding, our hypothesis 
that AUEC0–4h IMPDH is a true description of the net immunosuppression 
exerted by MPA must be true. Nevertheless, if that assumption is correct, T0 
IMPDH is the ideal parameter to use in the TDM of MPA, because it requires 
only a single blood sample and it is relatively robust with regard to timing. 
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10 Conclusions of the thesis 
 Pharmaceutical-grade albumin retains it binding capacity for naproxen in 
vivo. Serum from patients transfused with albumin has a better binding 
capacity for naproxen, digitoxin, and warfarin than serum from patients 
transfused with starch colloids. 
 The stabilizers present in pharmaceutical-grade albumin, N-acetyl-DL-
tryptophan and caprylate, displace naproxen from its binding site on 
albumin in vivo. The half-lives of these stabilizers in serum are short. 
Therefore, the clinical effect of the displacement reaction is probably 
negligible. 
 The free fraction of MPA correlates negatively with the albumin value in 
liver transplant recipients. 
 The total and free concentrations of MPA correlate equally well with 
IMPDH activity in CD4+ cells. 
 The T0 IMPDH measurement appears to be a robust measure of the 
immunosuppressive effect exerted by MPA in liver transplant recipients. 
 
 61 
11 Future perspectives 
Albumin solutions undoubtedly have a number of pharmacological properties. 
The historical studies in which albumin solutions have been used as a universal 
colloid, with little regard to its pharmacological properties, probably have little 
relevance in determining the place of albumin solutions in modern medicine. 
The pharmacological properties of albumin solutions should be explored in a 
more systematic way. Our work has demonstrated that albumin solutions retain 
their drug-binding properties in vivo. This might be exploited in some clinical 
settings in which a predictable and stable pharmacokinetic profile of a highly 
protein-bound drug is essential for the required outcome. One such setting, 
which would be interesting to explore, is the administration of highly cytotoxic 
drugs, such as etoposide, in anticancer protocols. Patients who receive this 
podophyllotoxin derivative comprise a group with highly variable albumin 
concentrations, attributable to the disease itself and as a consequence of the 
treatment. Alteration of the albumin concentration might result in a higher 
concentration of free drug, with a potentially enhanced effect. Alternatively, the 
increased free drug concentration might result in its more rapid elimination and a 
shorter half-life, with resulting treatment failure. Transfusion of these patients 
with albumin to keep their albumin levels stable during treatment may produce a 
more predictable pharmacokinetic profile and a consequently better outcome. 
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IMPDH activity is a pharmacodynamic marker that has shown promise as a 
parameter with which to tailor immunosuppressive treatments. Our research 
indicates that the T0 measurement is particularly robust. However, a clinical 
study correlating this measure with hard end-points, such as organ rejection and 
adverse MPA effects, is required to validate our findings. 
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